To overcome this obstacle, GLP-1 receptor agonists that have increased resistance to DPP-4 (such as exenatide and liraglutide) or DPP-4 inhibitors (such as sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin) have been used in animal and human studies [6,7]
There is no clinical rationale for this combination, and experienced researchers avoid it
Regular check-ins with your healthcare team are key
Fatty areas like the upper arms will likely hurt less than bonier parts of the body, like the hands, rib cage, or any joints
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Such cuts could reverse the strides weve made in addressing the obesity epidemic and exacerbate health disparities across our state